$3.76
0.154.16%
Last update: Oct 28, 7:51 PM
Unicycive Therapeutics Inc (UNCY) Stock Price, Quote, News & History
UNCYNASDAQ
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.
You can purchase shares of Unicycive Therapeutics (NASDAQ:UNCY) through any online brokerage.
Other companies in Unicycive Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Unicycive Therapeutics has a consensus price target of $37.88.
The stock price for Unicycive Therapeutics (NASDAQ: UNCY) is $3.76 last updated October 28, 2026 at 7:51 PM EDT.
There are no upcoming dividends for Unicycive Therapeutics.
Unicycive Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Unicycive Therapeutics.
Unicycive Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product...
